Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (807)	7/12/1999 4:45:00 PM
From: LLCF	Read Replies (1) \| Respond to of 2001

<Remember that market maker shorts are not reported, and you can also get shorts involving options that won't show up in the reported figures, but will still ultimately impact the price. > Option open interest is tiny. MM's that I know would never stay short much of a stock like this, makes no sense and they know it. DAK

To: Biomaven who wrote (807)	7/12/1999 4:50:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2001

>> More likely it's just some <5% institution selling and you'll never find out who. << Nope, too many shares. Oesterling has done a "johnson" at limiting dilution. >> Remember that market maker shorts are not reported, and you can also get shorts involving options that won't show up in the reported figures, but will still ultimately impact the price. << I didn't know that. Good, maybe there's some rationale for this irrational range that we've been captured in. >> noticed at least one fairly sophisticated short - i.e., one who knows enough details to sound superficially plausible. << I don't think (s)he's a short. I think (s)he's a stalker.

To: Biomaven who wrote (807)	7/12/1999 5:22:00 PM
From: scaram(o)uche	Respond to of 2001

Haven't yet reviewed the Yahoo! thread in detail. I saw the post that you are most likely referring to, and I got an email note from Spyros indicating that the thread was hopping last week. I'll take a look within the next couple of days. Spyros' reply was artistic..... only one center listed was among those targeted by GLIA..... at that center, the surgeon that had been using -L had relocated. Sales have resumed. Problems with wound healing? Preclinical says bull. Published studies say bull. Throughout all of the clinical studies reviewed by FDA, never heard a single whisper that healing was an issue. I'll lean to the published studies from dogs, at least for now.